Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RC28-E versus aflibercept in wet age-related macular degeneration
CTR20230065Phase 3Completed
- Sponsor
- RemeGen
- Start
- Mar 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eflimrufusp alfa in exudative macular degeneration, sponsored by RemeGen. Started Mar 2023; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20230065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230065.